Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 1-Year High - Here's What Happened

Key Points

• Amneal Pharmaceuticals reached a new 52-week high, trading above $19.74 and last quoted at $20.0580, up from its prior close of $18.71.
• Analyst sentiment remains favorable: eight analysts rate the stock a Buy and one rates it Hold, producing a consensus “Moderate Buy” rating and an average price target of $20.14. UBS recently raised its target to $25.
• The company exceeded quarterly earnings expectations, reporting $0.30 in EPS versus the $0.24 consensus estimate on $796.2 million in revenue; however, insiders sold 413,016 shares worth approximately $7.2 million over the past 90 days.

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) hit a new 52-week high on Monday . The stock traded as high as $19.74 and last traded at $20.0580, with a volume of 408257 shares trading hands. The stock had previously closed at $18.71.

Analyst Ratings Changes

AMRX has been the topic of a number of research analyst reports. UBS Group lifted their target price on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. Leerink Partners initiated coverage on shares of Amneal Pharmaceuticals in a research report on Wednesday, September 9th. They set an "outperform" rating and a $23.00 price objective for the company. Zacks Research cut shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 7th. JPMorgan Chase & Co. restated an "overweight" rating and issued a $22.00 price target on shares of Amneal Pharmaceuticals in a research report on Wednesday, August 26th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. Eight analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $20.14.

Amneal Pharmaceuticals Price Performance

The stock has a 50-day moving average of $17.84 and a two-hundred day moving average of $15.17. The firm has a market cap of $6.47 billion, a price-to-earnings ratio of 41.49 and a beta of 1.24. The company has a current ratio of 2.20, a quick ratio of 1.44 and a debt-to-equity ratio of 77.65.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.The firm had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. On average, analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.94 EPS for the current year.

Insider Activity at Amneal Pharmaceuticals

In related news, EVP Nikita Shah sold 146,403 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the transaction, the executive vice president owned 253,390 shares of the company's stock, valued at approximately $4,436,858.90. This trade represents a 36.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director John Kiely sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $17.64, for a total transaction of $882,000.00. Following the transaction, the director owned 210,252 shares in the company, valued at approximately $3,708,845.28. The trade was a 19.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 413,016 shares of company stock worth $7,216,567. 17.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Public Employees Retirement System of Ohio acquired a new stake in Amneal Pharmaceuticals during the 2nd quarter worth about $29,000. KBC Group NV acquired a new position in shares of Amneal Pharmaceuticals in the 1st quarter valued at about $80,000. Global Retirement Partners LLC purchased a new stake in shares of Amneal Pharmaceuticals in the fourth quarter worth approximately $115,000. Strs Ohio lifted its position in shares of Amneal Pharmaceuticals by 158.5% in the first quarter. Strs Ohio now owns 10,600 shares of the company's stock worth $132,000 after purchasing an additional 6,500 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in shares of Amneal Pharmaceuticals during the first quarter worth approximately $133,000. 31.82% of the stock is owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include dosage forms such as tablets, capsules, injectables, ophthalmic products and inhalation therapies, with a focus on complex generics and other products that can be more difficult to develop or manufacture.

The company also markets branded specialty pharmaceuticals in areas including central nervous system disorders, endocrinology, metabolic disease and other therapeutic categories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.